Filament Health CorpCBOE Canada:FHView on OTCQB
- LAST PRICE0.0300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0300/ 3
- Ask / Lots0.0400/ 118
- Open / Previous Close0.0350 / 0.0300
- Day Range
- 52 Week Range
- Volume54,860
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FH |
|---|---|---|
| 10:04 ET | 11000 | 0.035 |
| 10:42 ET | 10000 | 0.035 |
| 10:44 ET | 11000 | 0.035 |
| 11:48 ET | 5000 | 0.03 |
| 11:59 ET | 14000 | 0.04 |
| 04:00 ET | 3000 | 0.03 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Filament Health Corp | 7.9M | -1.4x | --- |
Scryb Inc | 6.4M | -0.4x | --- |
CardioComm Solutions Inc | 3.9M | -16.1x | --- |
H-Source Holdings Ltd | 12.1M | -3.6x | --- |
ZoomMed Inc | 2.1M | 1.4x | --- |
Izotropic Corp | 3.4M | -1.2x | --- |
Company Information
Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company’s platform of intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of Psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral delivery (1mg and 25mg), PEX020 Psilocin - oral delivery (dose withheld), and PEX030 Psilocin - sublingual delivery (dose withheld). The Company's preclinical stage drug candidates include AEX010 Ayahuasca - oral delivery (dose withheld), and AEX020 Monoamine Oxidase Inhibitor - oral delivery (dose withheld). The Company’s internal drug discovery and development program is carried out by its wholly owned subsidiary, Psilo Scientific Ltd., and is focused on developing standardized pharmaceutical-grade drug candidates from botanical psychedelic biomass.
Contact Information
- Headquarters
- 210-4475 Wayburne DriveBURNABY, BC, Canada V5G 4X4
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Gregory Mills
- Chief Executive Officer, Director
- Benjamin Lightburn
- Interim Chief Financial Officer
- Steven Nguyen
- Corporate Secretary, Director
- Jon Conlin
- Director
- Michael Messinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.9M |
|---|---|
Revenue (TTM) | $2.5M |
Shares Outstanding | 261.8M |
Filament Health Corp does not pay a dividend. | |
Beta | 1.50 |
EPS | $-0.02 |
Book Value | $0.01 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 3.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -181.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
